The mRNA levels of human cytochrome P450 (CYP)2Cs and CYP3As in primary cultures of freshly isolated human hepatocytes were assessed after exposure to NO-1886 and rifampicin, a typical inducer of CYP3As. mRNA levels were analyzed by real-time RT-PCR using an ABI PRISM 7700 Sequence Detector system. Exposure to NO-1886 for 24 hr at a concentration of less than 10 mM showed only a tendency to reduce or increase the expression levels of CYP2C8, CYP2C9, CYP2C19, CYP3A4, or CYP3A5 mRNA. A higher concentration (50 mM) of NO-1886 induced an increase in CYP2C8 mRNA and a decrease in CYP2C19 mRNA, and these changes continued after additional culture for 24 hr in fresh medium without NO-1886. The expression level of CYP3A4 mRNA after exposure to NO-1886 for 24 hr at 50 mM was about twice that in controls. Following additional culture for 24 hr in fresh medium without NO-1886, the expression of CYP3A4 mRNA was comparable to that in controls. On the other hand, the expression levels of CYP2C9 and CYP3A5 mRNA showed small and variable changes in each donor even at a high concentration (50 mM) of NO-1886.
Introduction
It has been reported that the novel compound NO-1886 (ibrolipim) (Fig. 1) is an eŠective lipoprotein lipase activator and that long-term administration of NO-1886 also protects against the development of experimental atherosclerosis in animals.
1) It has also been reported that NO-1886 improves obesity in rats through the induction of fatty acid oxidation-related enzymes such as long-chain acyl-CoA dehydrogenase and acetyl-CoA acyltransferase.
2) Moreover, Niho et al. 3) recently reported that NO-1886 may be useful as a chemopreventive agent for colon cancer.
Morioka et al. [4] [5] [6] have previously reported the pharmacokinetics and metabolic pathways ( Fig. 1) of NO-1886. The in vivo metabolic pathways of NO-1886 in the rat and the cynomolgus monkey have been identiˆed as the O-deethylation of phosphonate and the hydrolysis of the amide bond. 4, 6) The main metabolite is monoethyl phosphonate (M-2), which has been reported to account for 70z and 94z of all metabolites in the rat 4) and the cynomolgus monkey, 6) respectively. It has been demonstrated that the O-deethylation of phosphonate is performed by liver CYP isoforms and that the amino bond is hydrolyzed by liver microsomal carboxylesterase (CES). 5) In contrast, human liver microsomes have been reported to exhibit only O-deethylation of NO-1886. 5) Both CYP3A4 and CYP2C8 are major CYP isoforms involved in the phosphonate O-deethylation of NO-1886 in the human liver. 5) It has been demonstrated that the high-and low-a‹nity components for the metabolism of NO-1886 are CYP2C8 and CYP3A4, respectively, and the O-deethylation rate in human liver microsomes would imply minimalˆrst-pass metabolism and slow elimination of NO-1886 from the body. 5) We recently reported that CYP3A4 mRNA levels in primary cultures of cryopreserved human hepatocytes were signiˆcantly increased by exposure to NO-1886 at 50 mM in comparison with untreated control hepatocytes, but that CYP3A5 mRNA levels were not increased. 7) However, it is still unclear at the moment whether exposure to NO-1886 aŠects the mRNA levels of CYP2C8, which is the high-a‹nity component for the O-deethylation of NO-1886.
We therefore studied the induction of CYP2Cs and CYP3As in freshly isolated human hepatocytes. Furthermore, in order to assess the eŠects of repeated administration of NO-1886 on metabolic activity, NO-1886 was orally administered to female rats, and the plasma concentrations of NO-1886 and the expression levels of CYP isoforms in the liver were determined.
Methods

Materials:
The NO-1886 used in this study was synthesized at Otsuka Pharmaceutical Co., Ltd. (Tokushima, Japan) and had a chemical purity of 99.9z. Collagenase, rifampicin, and phenobarbital were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). The antigenic component reactive with polyclonal anti-CYP antibody against CYP1A2, CYP2B2, CYP2C12, CYP2E1, CYP3A2, and CYP4A1 was purchased from Daiichi Pure Chemicals Co., Ltd.
(Tokyo, Japan). Human liver specimens were obtained from the National Disease Research Interchange (NDRI) in the USA through the HAB Consortium in Japan. The characteristics of the four donors are shown in Table 1 purchased from Dainippon Pharmaceutical Co., Ltd. (Osaka, Japan). All other chemicals used in this study were of reagent grade.
Animals: The study was conducted using 7-weekold female Sprague-Dawley rats purchased from Charles River Japan, Inc. (Kanagawa, Japan). The rats were allowed free access to food and water. The present study was approved by the Committee on the Care and Use of Laboratory Animals of Otsuka Pharmaceutical Factory, Inc.
Administration to female rats: NO-1886 or phenobarbital was placed in an agate mortar and micronized with a small amount of 5z acacia suspension. The compound was then diluted with 5z acacia suspension to obtain NO-1886 dosing solutions at concentrations of 3, 10, and 30 mg W 10 mL or a phenobarbital dosing solution at a concentration of 80 mg W 10 mL. The dosing solutions for NO-1886 and phenobarbital were administered to the female rats orally at 10 mL W kg via a stomach tube once daily for 1 day, 7 days, or 14 days.
Blood sampling and analysis: Blood samples (approximately 0.3 mL) were drawn from the tail vein at 15, 30, and 45 min and 1, 2, 4, 6, 9, and 24 hr after the 1st, 7th, and 14th doses in female rats. Plasma NO-1886 concentrations were determined by high-performance liquid chromatography (HPLC). 6) From the plasma concentration proˆle, the maximum plasma concentration (Cmax) and the time point of the maximum plasma concentration (Tmax) were obtained. The elimination half-life (T 1 W 2 ) was estimated as ln 2 W k, where k is the slope of the terminal linear portion of the logarithmic plasma concentration-time curve. The area under the plasma concentration-time curve (AUC0-24) was calculated by the trapezoidal rule.
Preparation of rat liver microsomes: The rats were killed by decapitation under the light ether anesthesia and the liver was immediately perfused in situ with ice-cold 0.9z (w W v) NaCl solution. The liver was homogenized with 5 bed volumes of 1.15z (w W v) KCl using a Potter-Elvehjem homogenizer with a Te‰on pestle, and the liver homogenate was centrifuged at 9,000×g for 20 min. The resulting supernatant was then ultracentrifuged at 105,000×g for 1 hr. The resulting microsomal pellet was suspended in 10 mM Tris acetate buŠer (pH 7.4) containing 1 mM EDTA, 20z (v W v) glycerol, and 400 mM PMSF.
Determination of total CYP content: Hepatic microsomal CYP content was determined according to the method of Omura and Sato. 8) Protein concentration was estimated by the method of Lowry et al. 9) using BSA as the standard.
SDS-PAGE and immunoblot analysis: The liver microsomes were solubilized in sodium dodecyl sulfate (SDS) and resolved by polyacrylamide gel (10z w W v) electrophoresis according to the method of Laemmli.
10)
Antigenic components reactive with polyclonal antibodies raised against various CYP isoforms (CYP1A2, CYP2B2, CYP2C12, CYP2E1, CYP3A2, and CYP4A1) were visualized with 4-chloro-1-naphthol in the presence of 0.006z hydrogen peroxide and peroxidase-labeled anti-gout IgG in 0.05 M Na, K-phosphate buŠer (pH 7.4). The bands were semiquantitatively assayed using a computer imaging analysis system (BIORAD, Hercules, CA, USA).
Isolation and primary culture of rat hepatocytes: Perfusion of the liver of 7-week-old female rats was performed as described by Moldeus et al. 11) Brie‰y, the rat liver was perfused with Ca 2＋ ,Mg 2＋ -free Hanks solution (pH 7.4) containing 0.5 mM EDTA at 379 C for 4 min and further perfused with Hanks solution (pH 7.4) containing 0.1z collagenase type IV and 0.05z trypsin inhibitor at 379 C for 6 min. Hepatocytes were liberated from the perfused liver by blunt dissection and dispersed by gentle shaking in Ca 2＋ ,Mg 2＋ -free Hanks solution (pH 7.4). Afterˆltration through gauze, the hepatocytes were separated from nonparenchymal cells by centrifugation three times at 50×g for 3 min at 49 C, with the cells washed and resuspended in Ca 2＋ ,Mg 2＋ -free Hanks solution (pH 7.4) each time. Finally, the cells were resuspended in Williams' medium E (pH 7.4) containing 10z FCS, 4 mg W mL bovine insulin, 100 IU W mL penicillin, and 100 mg W mL streptomycin and seeded at 2.5×10 5 viable cells W mL into 24-well plates (Asahi Technoglass Co., Ltd., Tokyo, Japan) coated with collagen type I at a concentration of 1×10 5 viable cells W 0.4 mL W well. Cell suspensions with viability À90z as assessed by trypan blue exclusion were used for the experiments. The number of cells was counted using a Coulter counter. The cells were cultured for 3 hr after inoculation under 5z CO 2 and 95z air at 379 C. The medium was then replaced with fresh Williams' medium E (pH 7.4) containing 10z FCS, 4 mg W mL bovine insulin, 100 IU W mL penicillin, and 100 mg W mL streptomycin, and the cells were cultured for 21 hr under 5z CO 2 and 95z air at 379 C. The medium was then replaced with fresh Williams' medium E (pH 7.4) containing 3z BSA, and the cells were cultured for 24 hr under 5z CO2 and 95z air at 379 C.
CYP induction in primary cultures of rat hepatocytes: Hepatocytes cultured for 48 hr after inoculation were exposed to rifampicin, phenobarbital, or NO-1886 for 24 hr. Rifampicin, phenobarbital, and NO-1886 were dissolved in DMSO and diluted with Williams' medium E (pH 7.4) containing 3z BSA (without 10z FCS), and 4 mg W mL bovine insulin to concentrations of 10 mM, 50 mM, and 2-50 mM, respectively. Theˆnal concentration of DMSO was maintained at 0.1z (v W v). Control cells were also exposed to DMSO at a concentration of 0.1z (v W v). Total RNA was extracted from the hepatocytes using the QIAshredder TM and Rneasy } Mini Kit. The experiments were performed using triplicate hepatocyte cultures.
Isolation and primary culture of human hepatocytes: Perfusion of the human liver was performed according to the Seglen method.
12) The liver was perfused with Ca 2＋ ,Mg 2＋ -free Hanks solution (pH 7.4) containing 0.5 mM EDTA at 379 C for 10 min and further perfused with Hanks solution (pH 7.4) containing collagenase type IV and 1 mM Ca 2＋ at 379 C for 20 min. Then, the perfused liver was placed in another vesselˆlled with cold Hanks solution (pH 7.4) containing 2z BSA and 2 mM Ca 2＋ to obtain the hepatocyte suspension. After ltration of the hepatocytes through gauze, nonparenchymal cells were removed by centrifugation at 50×g for 3 min at 49 C. The hepatocytes were washed by suspending them in Hanks solution containing 2z BSA and 2 mM Ca 2＋ three times, and the isolated hepatocytes wereˆnally suspended in Waymouth Medium MB (pH 7.4) containing 10z FCS, 1 mM insulin, and 10 nM dexamethasone at concentrations ranging from 1×10 6 to 5×10 6 cells W mL. The hepatocytes were centrifuged (45×g, 49 C) for 3 min and resuspended in the hepatocyte culture medium. Viability was assessed by trypan blue dye exclusion ( Table 1 ). The hepatocyte suspension was diluted with hepatocyte culture medium to 2.5×10 5 viable cells W mL and seeded into 12-well plates (Asahi Technoglass Co., Ltd., Tokyo, Japan) coated with collagen type I at a concentration of 2×10 5 viable cells W 0.8 mL W well. The cells were cultured for 3 hr after inoculation under 5z CO2 and 95z air at 379 C. The medium was then replaced with fresh medium, and the cells were cultured for 21 hr under 5z CO2 and 95z air at 379 C. The medium was then replaced with fresh medium without human epidermal growth factor (hEGF), gentamicin, or amphotericin B, and the cells were cultured for 24 hr under 5z CO2 and 95z air at 379 C.
CYP induction in primary cultures of human hepatocytes: Hepatocytes cultured for 48 hr after inoculation were exposed to rifampicin or NO-1886 for 24 or 48 hr. Rifampicin and NO-1886 were dissolved in DMSO and diluted with hepatocyte culture medium to concentrations of 10 mM and 0.4-50 mM, respectively. Theˆnal concentration of DMSO was maintained at 0.1z (v W v). Control cells were also exposed to DMSO at a concentration of 0.1z (v W v). After an appropriate period of drug exposure, the medium was replaced with fresh hepatocyte culture medium without hEGF, gentamicin, or amphotericin B. Total RNA was extracted from the hepatocytes using the QIAshredder TM and Rneasy } Mini Kit. Three independent experiments were per- All sequences are shown from the 5? to 3? end. The positions of primers and probes were counted from the position of the initiation codon.
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Oligonucleotides: The pairs of forward and reverse primers and the TaqMan probes for human CYP2C8, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 used in the RT-PCR sequences are listed in Table 2 , 13) and the pairs of forward and reverse primers and the TaqMan probes for rat CYP1A2, CYP2B2, CYP2C12, CYP2E1, and CYP3A1 used in the RT-PCR sequences are listed in Table 3. 14) The primers and TaqMan probes were synthesized by QIAGEN (Tokyo, Japan). The TaqMan probes contained 6-carboxy‰uorescein (FAM) at the 5? end and 6-carboxytetramethyl rhodamine (TAMRA) at the 3? end and were designed to hybridize to a sequence located between the PCR primers.
TaqMan RT-PCR conditions: Total RNA was diluted to about 4 mg W mL with 50-mg W mL yeast tRNA. The RT-PCR assay was performed in 50 mL of TaqMan One-Step RT-PCR Master Mix reagents containing 300 nM forward primer, 900 nM reverse primer, 200 nM TaqMan probe, and about 20 ng of total RNA according to the method described previously.
7) The RT-PCR assay was performed using the ABI PRISM 7700 Sequence Detector system (Applied Biosystems) under the same conditions as in our previous studies. 7) Data analyses were performed with the ABI PRISM sequence detection software. The relative expression of each mRNA was calculated by the DCt method (where DCt is the value obtained by subtracting the Ct value for GAPDH mRNA from the Ct value for the target mRNA), as employed in our previous studies. 7, 15, 16) Speciˆcally, the amount of target mRNA relative to GAPDH mRNA is expressed as 2 -(DCt) . Data are expressed as the ratio of the target mRNA to GAPDH mRNA. The values indicate percentages relative to controls.
Statistical analysis: Statistical analysis was performed using the Student's t-test with a signiˆcance level of pº0.05.
Results
Study of in vitro CYP induction in primary cultures of human hepatocytes: In the present study, the levels of mRNA expression of CYP2C8, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 were evaluated in primary cultures of freshly isolated hepatocytes after exposure to NO-1886 and rifampicin, a typical inducer of CYP3As. The treatment of primary cultures of human hepatocytes with NO-1886 or rifampicin showed no signiˆcant toxic eŠects such as cell death or loss of adhesion. The levels of b-actin mRNA normalized to that of GAPDH mRNA were nearly the same in control hepatocytes and in hepatocytes treated with NO-1886 and rifampicin (data not shown). These data indicated that the expression of both GAPDH and b-actin mRNA were not aŠected by exposure to NO-1886 or rifampicin. Table 4 shows the mRNA expression levels of CYP2Cs and CYP3As in primary cultures of human hepatocytes after 24 hr exposure to NO-1886 at low concentrations (0.4, 2, and 10 mM) and to rifampicin (10 mM). The treatment of hepatocytes with rifampicin, a typical CYP3A4 inducer, caused an increase in the mRNA levels of CYP2C8 in addition to CYP3A4 and CYP3A5. The ratios of CYP mRNA levels in hepatocytes treated with rifampicin relative to those in control hepatocytes from donor #1 and donor #2 were 2.80 and 5.89 for CYP3A4, 2.59 and 2.01 for CYP3A5, and 1.47 and 2.34 for CYP2C8, respectively. These induction levels are similar to those reported in previous studies. Gerbal-Chaloin et al. 17) reported that treatment with rifampicin (10 mM) increased the mRNA expression levels of CYP2C8 and CYP2C19 by 1.5-8.5 fold and 1.0-2.7 fold, respectively, in comparison with controls. Bowen et al. 17) reported that treatment with rifampicin (50 mM) increased the mRNA expression level of CYP3A4 by 4.6-28 fold, in comparison with controls. Therefore, it appears that primary cultures of human hepatocytes as used in the present study are useful for evaluating commonly observed variations in mRNA expression levels.
Although the levels of CYP3A4 mRNA expression in the hepatocytes from both donors after exposure to NO-1886 (10 mM) were about 1.5 times higher than those in controls, the treatment of hepatocytes with low concentrations of NO-1886 (0.4, 2, and 10 mM) induced a slight change in the mRNA expression levels of CYP2Cs and CYP3As. Figure 2 shows the time course of changes in the expression levels of CYP2C8, CYP2C9, and CYP2C19 mRNA after exposure to a higher concentration of NO-1886 (50 mM) and rifampicin (10 mM). The levels of CYP2C8 mRNA expression in the hepatocytes from donor #3 and donor #4 after 24 hr exposure to rifampicin were 1.97 ( pº0.05) and 1.44 times higher than those in controls, respectively, as for the hepatocytes from donor #1 and donor #2 ( Table 3) . However, the elevated levels of CYP2C8 mRNA in the hepatocytes from donor #3 and donor #4 fell to control levels after 48-hr exposure to rifampicin and further 24 hr culture in fresh medium without rifampicin (72 hr in theˆgure). On the other hand, 24 hr exposure to a higher concentration of NO-1886 (50 mM) induced an increase in the expression levels of CYP2C8 mRNA, with increase ratios of 4.11 and 2.29 ( pº0.05) for the hepatocytes from donor #3 and donor #4, respectively. Furthermore, the elevation of CYP2C8 mRNA levels continued after 48-hr exposure to NO-1886 and further culture in fresh medium without NO-1886 (72 hr in theˆgure). Even after 24 hr culture in fresh medium, the expression levels of CYP2C8 mRNA in the hepatocytes from donor #3 and donor #4 were 2.22 and 2.60 (pº0.01) times higher than those in controls, respectively. The CYP2C9 mRNA level in hepatocytes from donor #3 was decreased at 24 hr by exposure NO-1886, but that in hepatocytes from donor #4 was increased at 24 hr and 48 hr. Interestingly, the levels of CYP2C19 mRNA in the hepatocytes from both donors fell after exposure to rifampicin and NO-1886, with NO-1886 showing a greater eŠect than rifampicin. Figure 3 shows the time course of changes in the expression levels of CYP3A4 and CYP3A5 mRNA after exposure to a higher concentration of NO-1886 (50 mM) and rifampicin (10 mM). Exposure to NO-1886 and rifampicin induced an increase in the levels of CYP3A4 mRNA in the hepatocytes from both donors. The ratios of the CYP3A4 mRNA levels in the hepatocytes treated with rifampicin relative to those in control hepatocytes from donor #3 and donor #4 were 5.24 ( pº0.001) and 6.07 ( pº0.001) for 24 hr exposure and 3.89 ( pº0.001) and 7.55 ( pº0.001) for 48 hr exposure, respectively. Even after further 24 hr culture in fresh medium without rifampicin (72 hr in theˆgure), the levels of CYP3A4 mRNA expression in the hepatocytes from Human hepatocytes were treated with rifampicin (10 mM) and NO-1886 (50 mM) for 24 and 48 hr. After exposure to drugs for 48 hr, the medium was replaced with fresh medium without drugs, and the hepatocytes were cultured for an additional 24 hr (72 hr in theˆgure). The medium was changed daily. Experiments (cultures of human hepatocytes) were performed in triplicate, and data are shown as mean SD. * pº0.05, ** pº0.01, and *** pº0.001 vs. controls at 0.1z DMSO. Fig. 3 . Time course of changes in levels of CYP3A4 and CYP3A5 mRNA expression after exposure to drugs.
Human hepatocytes were treated with rifampicin (10 mM) and NO-1886 (50 mM) for 24 and 48 hr. After exposure to drugs for 48 hr, the medium was replaced with fresh medium, and the hepatocytes were cultured for an additional 24 hr (72 hr in theˆgure). The medium was changed daily. Experiments (cultures of human hepatocytes) were performed in triplicate, and data are shown as meanSD. *pº0.05, **pº0.01, and ***pº0.001 vs. controls at 0.1z DMSO. donor #3 and donor #4 were 1.34 and 1.64 ( pº0.05) times higher than those in controls, respectively. In addition, the ratios of CYP3A4 mRNA levels in hepatocytes exposed to NO-1886 relative to those in control hepatocytes from donor #3 and donor #4 were 2.51 ( pº0.01) and 2.03 ( pº0.001) for 24 hr exposure and 1.97 ( pº0.01) and 1.79 for 48 hr exposure, respectively. Further 24-hr culture in fresh medium without NO-1886 (72 hr in theˆgure) caused the CYP3A4 mRNA levels to return to those in controls. The eŠects of rifampicin on the levels of CYP3A5 mRNA were similar to those observed for CYP3A4. However, NO-1886 showed no marked eŠects on the levels of CYP3A5 mRNA expression in the hepatocytes from both donors at any time point.
Study of CYP induction in female rats: Figure 4 shows the plasma concentrations of NO-1886 on the 1st, 7th, and 14th days of repeated oral administration of NO-1886 to female rats at a daily dose of 3 mg W kg. As shown in Fig. 4 , the Tmax and Cmax values for plasma NO-1886 concentrations were nearly the same for repeated administration for 1 to 14 days. Furthermore, the AUC0-24 and elimination half-life of plasma NO-1886 concentrations were not aŠected by the period of repeated administration up to 14 days. Table 5 shows the body weight, liver weight, total CYP content, and levels of various CYPs in female rats that received NO-1886 for 7 days at a daily dose of 3-30 Data are shown as mean±SD (n＝6). ** pº0.01 vs. controls. Rat hepatocytes were treated with phenobarbital (50 mM) and NO-1886 (2-50 mM) for 24 hr. Experiments (cultures of rat hepatocytes) were performed in triplicate. Data are expressed as percentages relative to controls and are shown as meanSD for primary cultures of hepatocytes from three diŠerent rats. mg W kg. As a positive control, phenobarbital was administered to female rats for 7 days at a daily dose of 80 mg W kg. The female rats that received phenobarbital showed increases in total CYP content and CYP2B2 and CYP3A1 W 2 protein levels. The expression levels of CYP2B2 and CYP3A1 W 2 protein were 11.6 ( pº0.01) and 7.28 ( pº0.01) times higher than those in controls, respectively. It seems that the mRNA expression levels of CYP2B2, CYP2C12, and CYP3A1 in primary cultures of rat hepatocytes were increased by exposure to phenobarbital at 50 mM (Fig. 5) . Those of CYP1A2 and CYP2E1 were not clearly increased by exposure to phenobarbital at 50 mM. On the other hand, repeated oral administration of NO-1886 at a daily dose of 30 mg W kg induced an increase in the total CYP level, but had only slight eŠects on the levels of hepatic microsomal CYP isoforms such as CYP1A2, CYP2B2, CYP2C12, CYP2E1, CYP3A1 W 2, and CYP4A1. In primary cultures of rat hepatocytes, the mRNA expression levels of isoforms other than CYP3A1 were not aŠected by exposure to NO-1886 at 2-50 mM (Fig. 5) , while CYP3A1 mRNA levels were increased, with large individual variation, by exposure to NO-1886 at 50 mM.
Discussion
Both CYP3A4 and CYP2C8 are major CYP isoforms involved in the phosphonate O-deethylation of NO-1886 in the human liver. 5) Since these two CYPs are the highand low-a‹nity components for the O-deethylation of NO-1886, respectively, hepatic metabolic activity depends on their expression levels in the liver. We have therefore focused on the induction of CYP2Cs and CYP3As in freshly isolated human hepatocytes. Morioka et al. 6) reported that the plasma Cmax value of NO-1886 at a dose of 3 mg W kg in the cynomolgus monkey was about 1.5 mg W mL (3.3 mM) and that protein binding in cynomolgus monkey plasma was 86.0z. The free plasma concentration of NO-1886 in the cynomolgus monkey was about 0.46 mM. Therefore, preliminary tests for the mRNA expression levels of CYP2Cs and CYP3As were performed with 24-hr exposure of primary cultures of freshly isolated human hepatocytes to NO-1886 at 0.4, 2, and 10 mM. However, 24-hr exposure to NO-1886 at 0.4 or 2 mM induced no changes in the mRNA expression levels of CYP2C8, CYP2C9, CYP2C19, CYP3A4, or CYP3A5, and exposure to NO-1886 at 10 mM induced slight changes in the mRNA expression levels of CYP2C8, CYP3A4, and CYP3A5. Therefore, it is thought that NO-1886 may not be related to the induction of CYP2C8, CYP2C9, CYP2C19, CYP3A4, or CYP3A5, based on the plasma concentration.
We recently also found that CYP3A4 mRNA levels were signiˆcantly increased in primary cultures of cryopreserved human hepatocytes by exposure to 50 mM NO-1886.
7) Furthermore, we studied the eŠects of exposure to a high concentration of NO-1886 (50 mM) on the mRNA expression levels of CYP2Cs and CYP3As. As shown in Fig. 3 , rifampicin, a typical CYP3A inducer, increased the levels of CYP3A4 mRNA in primary cultures of freshly isolated human hepatocytes after 24 hr and 48 hr exposure at 10 mM, with a return to control levels after changing to medium without rifampicin. Theseˆndings are consistent with our previous results for primary cultures of cryopreserved human hepatocytes.
13) NO-1886 (50 mM) also caused an increase in CYP3A4 mRNA levels, but its eŠect was much smaller than that of rifampicin even at a 5-fold higher concentration than rifampicin (10 mM). On the other hand, the induction eŠect of NO-1886 (50 mM) on the levels of CYP2C8 mRNA was greater than that of rifampicin (10 mM), and treatment with NO-1886 showed a tendency to maintain a higher level of CYP2C8 mRNA than in controls after changing to medium without NO-1886. It was demonstrated that CYP2C8, as the high-a‹nity component for the O-deethylation of NO-1886, was induced by exposure to NO-1886 as compared with other CYP isoforms. Interestingly, the levels of CYP2C19 mRNA decreased after 24-hr and 48-hr exposure to NO-1886 (50 mM), and these levels did not return to the control level after changing to medium without NO-1886. Although CYP2C19 is not involved in the metabolism of NO-1886, it was down-regulated by exposure to NO-1886. Further studies are needed to clarify the mechanism of this eŠect.
In order to demonstrate the in vivo changes in the expression levels of CYP isoforms after repeated administration of NO-1886, NO-1886 was administered to female rats for 1 to 14 days. Female rats are considered to be more suitable for investigating CYP induction by xenobiotics. For example, the CYP induction eŠects of climbazole, an antimycotic, and an antidandruŠ agent have been found to be greater in female rats than in male rats. 19) Oxandrolone, a synthetic anabolic steroid exhibiting androgenic properties, has also been reported to induce CYP3A2 in female but not in male rats. 20) Furthermore, phenytoin, an anticonvulsant used to treat epilepsy, is well recognized potent inducer of CYP3A2 in female rats. 21) Therefore, the pharmacokinetics of NO-1886 was also investigated during repeated oral administration at a dose of 3 mg W kg (the presumed clinical dose) once a day for 14 days in female rats.
The Tmax, Cmax, elimination rate, and AUC0-24 values for plasma NO-1886 concentrations were almost same after the 1st, 7th, and 14th doses in female rats. In addition, repeated oral administration for 14 days at 10 and 30 mg W kg showed AUC0-24 values for plasma NO-1886 NO-1886 up to 14 days has no eŠect on the pharmacokinetic parameters of NO-1886 in female rats. The biotransformation of NO-1886 to monoethyl phosphonate (M-2), which is the main metabolite of NO-1886 in the rat, 4) is catalyzed by many CYP isoforms such as CYP2A, CYP2B1 W 2, CYP2D, and CYP3A2, and the major CYP isoform responsible for this biotransformation is CYP3A2 (Y. Morioka, unpublished observation). However, the content of major CYP isoforms was not changed after repeated oral administration of NO-1886 for 7 days, although the total CYP content in liver microsomes was increased at a dose of 30 mg W kg. This increase in total CYP content may represent the sum of small increases in several CYP isoforms, including other CYP isoforms (e.g., CYP2C7 or minor CYPs). Furthermore, the levels of CYP mRNA in primary cultures of rat hepatocytes were not aŠected by exposure to NO-1886 at 2 or 10 mM. After repeated oral administration of NO-1886 at a dose of 30 mg W kg once a day for 14 days, the Cmax value was 15.1 mg W mL. Taking into consideration the protein binding ratio in rat serum (93.2z), 6 ) the free plasma concentration of NO-1886 was about 2.3 mM. At this concentration, the levels of CYP mRNA were not changed, in agreement with the protein levels of CYP isoforms. Therefore, observing the changes in mRNA levels in rat hepatocytes following exposure to NO-1886 is useful way to predict changes in the protein levels of CYP isoforms in vivo.
The free plasma concentration of NO-1886 in humans was estimated to be 0.23 mM at a dose of 3 mg W kg, based on 93.3z protein binding of NO-1886 in human serum.
6) The fact that 2 mM of NO-1886 in the culture medium did not aŠect the mRNA expression levels of CYP isoforms suggests that the expression levels of CYP2Cs and CYP3As should not be aŠected by the administration of NO-1886 in the clinical setting. However, the intended targets of NO-1886 in clinical use are the chemoprevention of diseases such as colon cancer 3) and atherosclerosis, 1) which would require longterm drug therapy and may also involve the co-administration of other drugs. Therefore, it is thought that monitoring the changes in the blood concentrations of co-administered drugs may be important for avoiding side eŠects during clinical studies of NO-1886.
In conclusion, it is expected that the expression levels of CYP2Cs and CYP3As should not change in clinical studies of NO-1886. Furthermore, primary cultures of both freshly isolated and cryopreserved human hepatocytes may be useful in preclinical drug development to evaluate the induction and recovery of drug-metabolizing enzymes in humans.
